Dagens industri recommends a Buy rating on medical technology company Elekta and sees around 30 percent upside over a one-year horizon, according to an analysis under the heading Stock of the Week.
The valuation is historically low, while Di expects 5 percent growth this year and 6 percent next year. A higher share of software and services, as well as efficiency improvements, is expected to lift margins.
Over a few years, Di assesses that the stock could double if growth reaches 7 percent and the operating margin improves to 15 percent. The dividend yield is 4.6 percent.
